Skip to content
Open access

The effects of hyperbaric oxygen therapy and mitochondrial transplantation on cisplatin toxicity.

Sep 2026 · Experimental and molecular pathology (Print) · Vol 148, pp. 105076 · 0 citations · 16 references
Medicine

Abstract

Cisplatin is an effective chemotherapeutic agent with dose-limiting toxicity in non-target tissues. Hyperbaric oxygen therapy (HBOT) and mitochondrial transplantation (MitoTr) have been explored as supportive strategies in preclinical models. We examined whether HBOT and/or MitoTr modulate cisplatin-associated reductions in MTT metabolic activity and oxidative balance in healthy human mesenchymal stem cells (hMSCs) under incubator versus hyperbaric conditions. Bone marrow-derived hMSCs were seeded at 5 × 103 cells/well and exposed to cisplatin at an experimentally determined MTT-based LD50 (148 μM; 150 μM used). A delayed adjunctive intervention protocol was applied after LD50-level exposure: cisplatin or vehicle for 24 h, followed by 4 h MitoTr co-incubation (10× or 100× cell-number-scaled dose), then three HBOT sessions (90 min, 2.1 ATA) or matched incubator control. Endpoints were MTT absorbance (NAD(P)H-dependent oxidoreductase activity), total antioxidant status, total oxidant status, and oxidative stress index, analyzed by two-way ANOVA with Tukey post hoc. At 150 μM cisplatin, MTT absorbance was markedly reduced in all cisplatin-containing groups under both conditions (all p < 0.001 vs controls), and neither HBOT nor MitoTr restored MTT signal to control levels. Among cisplatin-free groups, M10 under HBOT exceeded control HB MTT absorbance (p = 0.009), whereas M10 under incubator conditions did not differ from control. HBOT reduced baseline MTT absorbance in cisplatin-free groups relative to matched incubator controls (p < 0.001). MitoTr lowered oxidant status under incubator conditions; HBOT improved redox indices in mitochondria-free groups. Under the LD50-level conditions tested, neither HBOT nor MitoTr restored NAD(P)H-dependent oxidoreductase (MTT) activity in hMSCs. Under non-toxic conditions, both modalities produced context-dependent redox changes. Whether lower, clinically relevant cisplatin exposures would yield partial protection remains an open question.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.